drugset / Trial / NCT06625827

A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)

NCT06625827 ↗

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The goal of the study is to learn what happens to levels of digoxin in a healthy person's body over time. Researchers will compare what happens to digoxin in the body when it is given with and without another medicine called nemtabrutinib. Researchers are testing if digoxin levels in the body are different when digoxin is given with or without nemtabrutinib.

Timeline

Start
2023-11-07
Primary completion
2024-01-22
Completion
2024-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified — Oral
Subject Nemtabrutinib Other / unclassified — Oral

Indications

No indication recorded.